Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Physiologic Progesterone Not Associated with Breast Cancer in WHI Trial

October 29, 2015 8:30 am | by Cynthia Fox, Science Editor | Articles | Comments

A prominent editorial, finding breast cancers arose in the massive 16,000-patient Women’s Health Initiative (WHI) study due to “progesterone,” is outright wrong, wrote a top gynecologist and a top oncologist in a recent JAMA Oncology. Read more....


Boehringer Ingelheim’s Biosimilar Candidate: Phase I Study Results

October 28, 2015 4:02 pm | News | Comments

​Boehringer Ingelheim announced results from a Phase I study of its biosimilar candidate for adalimumab (AbbVie’s Humira), that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products. Read more...


Retroviral RNA May Play a Part in Liver Cancer

October 28, 2015 3:55 pm | by RIKEN | News | Comments

An international group led by RIKEN in Japan and INSERM in France have found that retroviral long-terminal-repeat (LTR) promoters—a type of repetitive element that are widely distributed in the human genome—are highly activated in hepatocellular carcinomas, the most common type of liver cancer. Read more...


Astellas Inititaties Phase 3 Registration Trial of Gilteritinib in Relapsed or Refractory AML

October 28, 2015 3:43 pm | News | Comments

Astellas Pharma Inc. yesterday announced dosing of the first patient in a randomized Phase 3 registration trial of gilteritinib (ASP2215) versus salvage chemotherapy in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The primary endpoint of the trial is overall survival (OS). Read more...


Bipolar Patients' Brain Cells Predict Response to Lithium

October 28, 2015 3:37 pm | News | Comments

The brain cells of patients with bipolar disorder, characterized by severe swings between depression and elation, are more sensitive to stimuli than other people's brain cells, researchers have discovered. Read more...


Asthma Drug Found to Rejuvenate Older Rat Brains

October 28, 2015 3:31 pm | News | Comments

A European team of researchers working in Austria has found that a drug commonly prescribed to treat asthma can lead to rejuvenation in an older rat brain. In their paper published in the journal Nature Communications, the group describes their study that involved giving the drug to rats and then testing them on their cognitive and memory abilities. Read more...


New Incretin-Based Medicines Will Allow Weight and Diabetes Control With a Single Weekly Dose

October 28, 2015 3:26 pm | by Universidade de Vigo | News | Comments

The new generation of incretin-based medicines will allow a coordinated action against the combination diabetes/obesity, also known as diabesity, in some cases with only a single weekly dose, and with the likelihood of additional beneficial effects on other health complications related to this condition, such as cardiovascular and neurodegenerative diseases. Read more...


Amgen’s Oncolytic Drug Wins FDA Approval for Melanoma

October 28, 2015 12:03 pm | by Stephanie Guzowski, Editor | News | Comments

The FDA on Tuesday approved Amgen’s first-of-a-kind immunotherapy injection that uses the herpes virus to fight inoperable melanoma that has undergone first-line therapy. The injection called talimogene laherparepvec, or T-Vec, is an oncolytic immunotherapy that uses a genetically modified strain of the herpes virus to invade tumors and replicate itself, killing cancer cells and priming the immune system to attack the disease.


UM Baltimore Grants Glycocept Rights to Therapeutic Monoclonal Antibodies Technology

October 28, 2015 10:48 am | News | Comments

University of Maryland (UM) Ventures and Glycocept, Inc. announced today that the University of Maryland, Baltimore (UMB) has granted Glycocept worldwide, exclusive licensing rights to a UMB patent and technology to modify monoclonal antibodies to alter their effector functions. Read more...


Drug Prices Top Americans' List of Health Care Concerns

October 28, 2015 10:43 am | by Matthew Perrone, AP Health Writer | News | Comments

Americans from across the political spectrum are worried about the cost of prescription drugs for serious diseases, following weeks of news coverage about companies hiking prices for critical medicines. Read more...


Alerting the Immune System's Watchmen to Improve Vaccines

October 28, 2015 10:39 am | by American Chemical Society | News | Comments

Today, in ACS Central Science, researchers report a new way to help improve vaccines using molecules that more effectively direct the immune system. Read more...


Boehringer Ingelheim's New Sub-Analyses for Stiolto Respimat

October 28, 2015 10:12 am | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of several new post-hoc analyses from the TONADO 1&2 and OTEMTO 1&2 studies at the American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal. Read more...


New Treatment Option for Nonfunctional Neuroendocrine Tumors of the Lung and Gastrointestinal Tract

October 28, 2015 10:04 am | News | Comments

The results of the international, multicenter, Phase 3 RADIANT-4 study clearly demonstrate the efficacy of the agent everolimus in treating nonfunctional neuroendocrine tumors of lung or gastrointestinal origin. Read more...


Intercept Pharmaceuticals: Results of Phase 2 Trial of OCA in NASH Patients in Japan

October 28, 2015 9:27 am | News | Comments

Intercept Pharmaceuticals, Inc. (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, today announced the results of a 72-week Phase 2 dose ranging trial of obeticholic acid (OCA), Intercept's lead FXR agonist, in adult patients with nonalcoholic steatohepatitis (NASH) in Japan. Read more...


Merck's Pembrolizumab: Overall Survival Compared to Chemo in Patients with Previously Treated Advanced NSCLC

October 28, 2015 9:16 am | News | Comments

Merck, known as MSD outside Canada and the United States, today announced topline results from the KEYNOTE-010 study of pembrolizumab in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.